A PHASE II TRIAL OF REDUCED DOSE BRENTUXIMAB VEDOTIN FOR CUTANEOUS T‐CELL LYMPHOMAS. (17th June 2021)

• Record Type: Journal Article
• Authors: Khan, N.; Noor, S.; Geller, S.; Khodadoust, M. S.; Kheterpal, M.; Hancock, H.; Davey, T.; Ryu, S.; Perez, L.; Lares, A.; Ganesan, N.; Sohail, S.; Santarosa, A.; Galasso, N.; Kim, E.; Myskowski, P.; Kim, Y. H.; Horwitz, S.; Moskowitz, A.
• Is Part Of: Hematological oncology. Volume 39(2021)Supplement 2
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-06-17
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.123_2880
• Languages: English
• ISSNs: 0278-0232